Skip to main content
Biosynex logo

Biosynex — Investor Relations & Filings

Ticker · ALBIO ISIN · FR0011005933 LEI · 969500H4BGE1HBLGP566 PA Manufacturing
Open in API
Filings indexed 202 across all filing types
Latest filing 2024-05-03 Declaration of Voting R…
Country FR France
Listing PA ALBIO

About Biosynex

https://www.biosynex.com/en/

Biosynex is a company that specializes in the design, manufacture, and distribution of medical diagnostic solutions. Its core product line consists of Rapid Diagnostic Tests (RDTs) for both professional use in clinical settings and for self-testing by the general public. The professional portfolio includes point-of-care (POC) instruments, molecular biology diagnostics (such as PCR tests), and a wide array of immunodiagnostic assays. For the consumer market, Biosynex offers various self-tests and a range of prevention and monitoring devices, including thermometers, blood pressure monitors, and pulse oximeters. The company focuses on providing simple, rapid, and effective tools for screening, diagnosis, and prevention.

Recent filings

Filing Released Lang Actions
BIOSYNEX SA: DÉCLARATION DU NOMBRE D’ACTIONS ET DES DROITS DE VOTE AU 30 AVRIL 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "DECLARATION DU NOMBRE D'ACTIONS ET DES DROITS DE VOTE AU 30 AVRIL 2024" and explicitly references Article L.233-8 II du Code de commerce and Article 223-16 du Règlement général de l'Autorité des Marchés Financiers (AMF). This content, which declares the total number of shares and voting rights as of a specific date, directly corresponds to the definition of a Declaration of Voting Results & Voting Rights Announcement. Although it is a declaration, it is not a result of a vote (DVA), but rather a mandatory disclosure of the capital structure for voting purposes, which fits best under the specific category DVA (Declaration of Voting Results & Voting Rights Announcements) as it relates directly to voting rights calculation, or potentially RNS if DVA is strictly interpreted as post-meeting results. Given the explicit mention of 'droits de vote' (voting rights) and the regulatory context, DVA is the most precise fit among the provided options, as it covers announcements related to voting rights.
2024-05-03 French
BIOSYNEX SA: LA FILIALE PROCISEDX ANNONCE UN ACCORD DE DISTRIBUTION AVEC REVVITY EUROIMMUN US POUR LA DISTRIBUTION DE LA PLATEFORME PROCISEDX AUX ETATS-UNIS ET AU CANADA
Regulatory Filings Classification · 100% confidence The document is a press release announcing a strategic distribution agreement between ProciseDx (a subsidiary of Biosynex) and Revvity EUROIMMUN US for the US and Canadian markets. It details the product (ProciseDx platform), the market opportunity (TDM for IBD patients), and includes quotes from management. Crucially, it contains a section titled "Prochaine communication" which explicitly states the date for the next financial update: "Chiffre d'affaires 2ème trimestre 2024 : jeudi 18 juillet 2024 après bourse". This structure—a significant business update combined with a forward-looking statement about the next financial release—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is not the full quarterly report (IR) or the official earnings release document itself, but rather a major business development announcement that precedes the formal earnings release, it fits best under the general category for corporate news that isn't strictly financial results or a regulatory filing fallback. However, given the context of major business updates often released alongside or instead of a formal ER, and the explicit mention of the upcoming revenue announcement, it strongly signals corporate news. Since it is a detailed announcement of a strategic event rather than a brief regulatory notice (RNS) or a formal financial report (ER/IR), and it is not a transcript (CT) or presentation (IP), the most appropriate classification for a significant, non-financial-results-focused corporate announcement is often the general Regulatory Filings (RNS) if no better fit exists, or potentially an Earnings Release (ER) if the market views this type of news as being released in lieu of or as part of the earnings cycle. Given the content is purely strategic partnership news, and not the actual financial results, it is not an ER. It is a significant corporate announcement. In the absence of a specific 'Corporate News' category, RNS (Regulatory Filings/General Announcement) is the standard fallback for non-standard, material corporate disclosures.
2024-04-29 French
BIOSYNEX SA: RÉSULTATS ANNUELS 2023 - FINALISATION DE L’INTEGRATION DES NOUVELLES FILIALES EN 2024 ET RETOUR ATTENDU À LA PROFITABILITÉ FIN 2025
Earnings Release Classification · 100% confidence The document is titled "RESULTATS ANNUELS 2023" (Annual Results 2023) and contains a detailed table of consolidated financial figures for the fiscal year ended December 31, 2023, comparing them to 2022. It explicitly mentions that the Board of Directors approved the 2023 accounts on April 22, 2024, which will be submitted to the upcoming general meeting. It also notes that the audit procedures for the 2023 accounts are ongoing ("Les procédures d'audit des comptes 2023 sont en cours"). This content strongly indicates a comprehensive annual financial report. Although it is presented as a summary/press release format, the core content is the full annual financial performance review, which aligns best with the Annual Report (10-K) definition, even if it might be a preliminary version or a press release accompanying the 10-K filing. Given the depth of the financial tables and the focus on the full fiscal year results, 10-K is the most appropriate classification for the underlying report type being summarized. It is not merely an Earnings Release (ER) as it covers the full year and includes extensive balance sheet/debt restructuring details, nor is it a simple Audit Report (AR) as it contains management discussion and forward-looking statements alongside the results. FY 2023
2024-04-24 French
BIOSYNEX SA: AVALUN LAURÉATE DES TROPHÉES DE LA HEALTHTECH POUR LE DÉVELOPPEMENT DE SON NOUVEAU TEST DE MESURE RAPIDE DU FIBRINOGÈNE
Regulatory Filings Classification · 100% confidence The document is a press release written in French announcing that AVALUN (a subsidiary of BIOSYNEX) won a HealthTech award for its new rapid fibrinogen test. It details the product's advantages, regulatory status (CE marking, FDA process), and market potential. Crucially, the document concludes with a section titled "Prochaine publication" (Next publication) stating: "Résultats annuels 2023, le 24 avril 2024, après Bourse." This indicates the document itself is an announcement or news item, not the actual Annual Report (10-K) or the detailed Interim Report (IR). Since it is a general corporate announcement about an award and future reporting schedule, and does not fit the specific definitions for Director's Dealing (DIRS), Dividend (DIV), Capital Change (SHA), or Earnings Release (ER) which usually contain hard numbers, the most appropriate general category for this type of corporate news release that doesn't fit elsewhere is Regulatory Filings (RNS), as it is a general announcement. However, upon reviewing the definitions, this document is primarily an announcement of an achievement/award, which is a form of corporate news. It is not a formal regulatory filing like a 10-K or a specific financial report. Given the options, RNS (Regulatory Filings / miscellaneous announcements) is the best fit for a general press release about an award and future reporting dates, as it is not a specific financial report, management change, or transaction notice.
2024-03-26 French
BIOSYNEX SA: CHIFFRE D’AFFAIRES 2023 PORTÉ PAR LA DYNAMIQUE DES ACQUISITIONS - REPRISE D’UNE TRAJECTOIRE DE CROISSANCE GLOBALE EN 2024
Earnings Release Classification · 97% confidence The document provides a summary of the company's 2023 financial performance, highlighting revenue figures ('CHIFFRE D'AFFAIRES 2023'), year-over-year comparisons, and commentary on business segments, including the impact of COVID-19 sales normalization and growth from acquisitions. It explicitly states that the figures are 'Chiffres non audités' (Unaudited figures) and announces the 'Résultats annuels 2023 le 24 avril 2024 après bourse' (Annual results 2023 on April 24, 2024 after market close). Since this document summarizes the results but is not the full, audited Annual Report (10-K) and is not explicitly an 'Earnings Release' (ER) which usually focuses only on key highlights before a more detailed report, its nature strongly suggests it is an Interim/Quarterly Report (IR) or a preliminary results announcement. Given the comprehensive nature of the financial tables and commentary covering the full year (2023), it functions as the primary release of period results, which aligns best with the 'Interim / Quarterly Report' (IR) category, even though it covers the full year, as it precedes the final audited filing. It is a results announcement, not just a notice of publication (RPA). FY 2023
2024-01-18 French
BIOSYNEX SA: DECLARATION DU NOMBRE D’ACTIONS ET DES DROITS DE VOTE AU 31 DECEMBRE 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document title is "DECLARATION DU NOMBRE D'ACTIONS ET DES DROITS DE VOTE AU 31 DECEMBRE 2023" (Declaration of the number of shares and voting rights as of December 31, 2023). It explicitly references French commercial code articles related to the declaration of the total number of shares and voting rights. This content directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes or related statutory declarations about voting power, even if it's a periodic update rather than a post-meeting result summary. It is a specific statutory disclosure regarding voting rights.
2024-01-03 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.